Singapore, Nov. 2 -- A new Singapore study found that around one in six (16.7%) higher-risk patients with hormone receptor-positive (HR+), HER2-negative early breast cancer whose cancer had not spread to the lymph nodes experienced recurrence or death within seven years. These "high-risk node-negative" patients had tumour or disease characteristics associated with a higher likelihood of recurrence despite having no lymph-node involvement. Their outcomes were comparable to those of patients whose cancer had spread to one to three lymph nodes, challenging the assumption that node-negative early breast cancer is always low risk.

Presented at the European Society for Medical Oncology Congress (ESMO 2026) in Madrid, the Real-World Assessment ...